SWINE VESICULAR DISEASE VIRUS (SVDV)
LEVELS: Highly unlikely: No controls necessary; Highly unlikely: No evidence of non-foodborne zoonotic transmission; Highly effective: Routine on-farm biosecurity measures are effective in preventing farm-to-farm transmission; Moderate: Clinical signs not unique but existing tests available at local/regional laboratory(s); Moderate: Manageable losses related to endemic (population) or chronic (individual) occurrence; Temporary disruption: Measureable negative effect on demand for less than a month when disease occurs on one or more farms; Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments; Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy; No availability: Effective treatments not currently available in the US (or have not been developed); No availability: Effective vaccines not currently available in the US (or have not been developed); Highly likely: Can be eradicated using existing tools and knowledge
OVERVIEW
Swine vesicular disease (SVD) is caused by Swine Vesicular Disease Virus (SVDV), an enterovirus closely related to human coxsackievirus B5. SVD emerged in Italy in 1966 and was subsequently diagnosed in multiple European and Asian countries, but has never been reported in North or South America. The disease was removed from the WOAH notifiable disease list in 2015 because modern diagnostic techniques easily differentiate SVDV from FMDV, and production losses from SVD are limited. Europe is currently free of SVDV—the most recent infections were reported in Portugal (2007) and Italy (2015), with Italy's final seropositive farm detected in 2017 through extensive monitoring. SVDV causes vesicular lesions clinically indistinguishable from those of foot-and-mouth disease, vesicular stomatitis, Seneca Valley virus, and vesicular exanthema virus, which historically made it a concern for FMD surveillance. However, the clinical signs of SVD are much milder than FMD—fever is rare, lameness is uncommon, and sudden death from myocarditis does not occur. Recent SVDV strains predominantly cause subclinical infections, with most Italian cases detected through serological monitoring rather than clinical observation. The virus is exceptionally stable in the environment, surviving for months in carcasses and processed meat products, which explains the historical importance of swill feeding in disease transmission. SVDV is resistant to many common disinfectants, with only sodium hydroxide (1%) providing reliable rapid inactivation. Importantly, SVDV isolates obtained after 1993 have lost the ability to infect human cells, eliminating earlier concerns about zoonotic potential.
FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No controls necessary
Although early concerns existed because SVDV is closely related to human coxsackievirus B5, the chapter states that "severe illness in humans caused by SVDV has not been confirmed, not even from laboratories working with large amounts of infectious virus." Critically, "SVDV isolates obtained after 1993 have lost the ability to infect human cells and, thus, any of their original zoonotic potential." The chapter concludes that "the absence of reports of human disease leads to the conclusion that SVDV is not a zoonosis." There is no foodborne risk to consumers.
NON-FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No evidence of non-foodborne zoonotic transmission
SVDV does not cause human disease. Despite extensive occupational exposure in laboratories, farms, and slaughterhouses over decades, no human infections have been documented. As noted above, post-1993 isolates have lost the ability to infect human cells entirely, confirming that contemporary SVDV strains pose no zoonotic risk through any route.
EFFECTIVENESS OF ON-FARM BIOSECURITY IN PREVENTING FARM-TO-FARM TRANSMISSION
Level: Highly effective: Routine on-farm biosecurity measures are effective in preventing farm-to-farm transmission
SVDV transmission occurs primarily through identifiable pathways that can be controlled with good biosecurity, but the virus's exceptional environmental stability creates challenges. Epidemiological studies identified main transmission sources as: movement of infected pigs (33%); contaminated transport vehicles (31%); other indirect routes (31%); and unknown sources (5%). The virus survives for months in carcasses, processed meat (including salami and pepperoni), and slurry, explaining the historical importance of swill feeding in transmission. Importantly, "SVD is considered a 'pen disease' rather than a farm disease"—spread between pens within a farm typically requires shared open drainage or frequent pig movement, and "separation of pigs significantly reduced SVDV transmission." The chapter notes that "pigs transported in properly cleaned and disinfected vehicles do not often get infected" and "even on farms where infection is present in one compartment, the infection does not spread easily to other compartments if strict hygienic measures are applied." Recent Italian outbreaks were largely detected through serological surveillance rather than clinical signs, suggesting subclinical transmission can occur undetected. Wildlife (wild boar) surveillance has not detected SVDV in affected regions, suggesting no wildlife reservoir.
DIFFICULTY OF DETECTING AND CONFIRMING INFECTION
Level: Moderate: Clinical signs not unique but existing tests available at local/regional laboratory(s)
Clinical detection is complicated by the mild nature of disease—recent strains "predominantly caused subclinical infections" and Italian cases were "never reported based on clinical disease, but always by detection of SVDV-specific antibodies in the monitoring program." When clinical signs occur, they are indistinguishable from FMD and other vesicular diseases, making laboratory confirmation mandatory. However, once SVD is suspected, laboratory diagnosis is straightforward: virus isolation in IB-RS-2 cells is highly sensitive; real-time RT-PCR provides rapid, sensitive detection in feces and organs; antigen-capture ELISA can detect and identify virus in vesicular material; and monoclonal antibody-based ELISA provides specific antibody detection with minimal false positives. The WOAH has adopted monoclonal antibody-based ELISA as the standard test. IgM and IgG ELISAs can estimate time of introduction on farms (though estimation beyond 50 days is not possible). The main diagnostic challenge is recognizing that vesicular disease may be present when clinical signs are subtle or absent.
FINANCIAL IMPACT ON FARM'S COST OF PRODUCTION
Level: Moderate: Manageable losses related to endemic (population) or chronic (individual) occurrence
SVD causes much milder clinical disease than FMD. The chapter notes that "production losses due to SVD are very limited"—this was a key reason the disease was removed from the WOAH notifiable disease list. Clinical signs include vesicles on coronary bands, snout, and occasionally udder/teats in lactating sows, but "in experimental studies, fever was rare, and lameness was almost never observed." Sudden death from myocarditis—common in young piglets with FMD—does not occur with SVDV. Most contemporary infections appear to be subclinical. Economic impact comes primarily from: (1) trade restrictions when detected in previously free countries; (2) costs of stamping out to regain disease-free status quickly; (3) surveillance and monitoring costs in endemic situations. The disease does not cause the catastrophic direct production losses associated with highly pathogenic diseases.
EFFECT ON DOMESTIC OR EXPORT MARKETS
Level: Temporary disruption: Measureable negative effect on demand for less than a month when disease occurs on one or more farms
Although SVD was removed from the WOAH notifiable disease list in 2015, "SVD is still considered a notifiable disease in many countries, particularly countries that export pigs and/or pork." Detection triggers regulatory investigation and potentially trade restrictions from importing countries that maintain SVD-free requirements. The chapter notes that "in the face of trade embargos resulting from SVD outbreaks, stamping out infected herd(s) is the quickest method to control the outbreak and regain SVDV-free status." The historical concern was that SVD could mask FMD outbreaks—"in the FMD outbreak in 1997 in Taiwan, the presence of SVDV in the country probably delayed the reporting of FMD cases, which may have led to more FMDV-infected farms." Market impacts are significant but less severe and prolonged than for FMD or other WOAH-listed diseases.
PATHOGEN'S ABILITY TO DEVELOP AND SPREAD RESISTANCE
Level: Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments
SVDV is a viral pathogen (positive-sense single-stranded RNA enterovirus) that does not carry, acquire, or transmit antimicrobial resistance genes. The virus poses no AMR concerns. Antigenic studies show only small differences among isolates—SVDV is considered to have a single serotype. Genetic evolution has been documented (four distinct phylogenetic groups based on VP1 sequences), including the loss of ability to infect human cells in post-1993 isolates, but this represents viral adaptation rather than antimicrobial resistance.
AMR DEVELOPMENT DRIVEN BY DISEASE MANAGEMENT
Level: Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy
No antiviral treatments exist for SVDV. Clinical disease is mild and self-limiting, typically requiring no treatment. In control programs, infected herds are stamped out rather than treated. Antimicrobials are not routinely used in SVD management. Secondary bacterial infections of ruptured vesicles might occasionally be treated, but this would represent rare, episodic individual animal treatment.
AVAILABILITY OF EFFECTIVE TREATMENT OPTIONS
Level: No availability: Effective treatments not currently available in the US (or have not been developed)
No specific treatments exist for SVDV infection. The disease is typically mild and self-limiting—affected pigs recover without intervention. Management focuses on preventing introduction (biosecurity) and eliminating infection when detected (stamping out or test-and-removal). No antiviral drugs are available or needed given the limited clinical impact.
AVAILABILITY OF EFFECTIVE VACCINES OR BACTERINS
Level: No availability: Effective vaccines not currently available in the US (or have not been developed)
The chapter states: "No SVDV vaccine is commercially available and vaccination of pigs in the field has not been undertaken." Experimental vaccines have been described, including inactivated virus vaccines, combination vaccines with FMDV, and subunit vaccines, and these "reportedly induced strong SVDV antibody responses." However, no commercial product has been developed because: (1) clinical disease is mild with limited production impact; (2) the disease has been eliminated from most previously affected countries through stamping out; (3) vaccination would complicate serological surveillance for disease freedom.
FEASIBILITY OF ERADICATING THE DISEASE FROM THE US
Level: Highly likely: Can be eradicated using existing tools and knowledge
SVDV has never been detected in the United States. Europe successfully eliminated SVDV through: stamping out of infected herds; thorough cleaning and disinfection; serological surveillance to detect subclinical infections; and control of swill feeding. The chapter notes that "elimination of SVDV by partial depopulation is feasible"—a test-and-removal procedure with removal of seropositive animals followed by disinfection was successful in the Netherlands. This approach works because "transmission of SVDV is limited from subclinically infected pigs" even though transmission is rapid during clinical infection. Key control measures include: banning swill feeding (critical given virus survival in meat products); proper cleaning and disinfection of transport vehicles; movement restrictions; and serological surveillance. If SVDV were introduced to the US, eradication would be achievable using established European protocols, though the virus's exceptional environmental stability and resistance to many disinfectants (only sodium hydroxide 1% is reliably effective) require careful attention to decontamination procedures.